Civitas Therapeutics
Civitas Therapeutics is a biopharmaceutical company that develops pulmonary delivery therapies founded in 2009 by Ron Cohen, Glenn V. Batchelder, James Wright, Martin Freed and Richard Batycky.
All edits
On January 10, 2011 Civitas Therapeutics completed their series A funding round with $20 million in funding from Longitude Capital and Canaan Partners.
On September 11, 2013 Civitas Therapeutics completed their series B round with $38 million in funding from Bay City Capital (lead investor), RA Capital Management, Longitudinal Capital, Fountain Healthcare Partners, Canaan Partners, and Alkermes.
On August 25, 2014 Civitas Therapeutics completed their series C funding round with $55 million in funding from Adage Capital Management, OrbiMed Advisors, Partner Fund Management, Rock Springs Capital, Sofinnova Ventures, Alkermes, Bay City Capital, Canaan Partners, Fountain Healthcare Partners, Longitude Capital, RA Capital, and Wellington Management Company.
Civitas Therapeutics is a biopharmaceutical company developing pulmonary delivery products that is headquartered in Chelsea, Massachusetts and was founded in 2009 by Glenn V. Batchelder, James WrightJames Wright, Martin Freed, and Richard Batycky.
Civitas Therapeutics is a biopharmaceutical company developing pulmonary delivery products that is headquartered in Chelsea, Massachusetts and was founded in 2009 by Glenn V. Batchelder, James Wright, Martin FreedMartin Freed, and Richard Batycky.
Civitas Therapeutics is a biopharmaceutical company developing pulmonary delivery products that is headquartered in Chelsea, Massachusetts and was founded in 2009 by Glenn V. Batchelder, James Wright, Martin Freed, and Richard BatyckyRichard Batycky.
Civitas Therapeutics is a biopharmaceutical company developing pulmonary delivery products that is headquartered in Chelsea, Massachusetts and was founded in 2009 by Glenn V. BatchelderGlenn V. Batchelder, James Wright, Martin Freed, and Richard Batycky.
Find more companies like Civitas Therapeutics
